Lancet Rheumatology柳叶刀风湿病学
Lancet Rheumatology(英文缩写 LANCET RHEUMATOL),ISSN 2665-9913,eISSN 2665-9913,中文译名:柳叶刀风湿病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 35.482 | Q1 |
| 2022 | 25.400 | Q1 |
| 2023 | 15.000 | Q1 |
| 2024 | 16.400 | Q1 |
| 2025 | 29.500 | Q1 |
Lancet Rheumatology 最新收录文献
-
1. Relevance of the 2025 ESC guidelines for the diagnosis and management of myocarditis and pericarditis for systemic autoimmune rheumatic diseases.
PMID:日期:2026-10-01The European Society of Cardiology (ESC) released new guidelines in 2025 for the management of myocarditis and pericarditis, which include systemic autoimmune rheumatic diseases as one of the potential aetiologies. Myopericardial involvement in systemic autoimmune rheumatic diseases is common and associated with poor outcomes; however, the unique pathophysiology of myopericardial involvement in systemic autoimmune rheumatic diseases poses specific challenges and limits the applicability of the generic diagnostic pathways proposed in the 2025 ESC guidelines to the systemic autoimmune rheumatic disease population. Myopericardial disease in patients with systemic autoimmune rheumatic disease is usually subclinical, often with atypical clinical presentation, and the accuracy of conventional biomarkers including advanced imaging, to detect myopericaridal disease is reduced in this population compared with the general population due to chronic inflamation. Management of myopericardial involvement in patients with systemic autoimmune rheumatic diseases primarily targets the underlying rheumatic disease; however, disease-specific guidance and multidisciplinary care pathways for the management of myopericardial involvement in patients with systemic autoimmune rheumatic diseases are urgently required and should be developed jointly by experts in both rheumatology and cardiology.
-
2. Diagnostic accuracy of musculoskeletal ultrasound in suspected polymyalgia rheumatica: a multicentre, cohort study.
PMID:日期:2026-10-01Diagnosing polymyalgia rheumatica is challenging, and musculoskeletal ultrasound is primarily used in diagnostically difficult situations. Previous musculoskeletal ultrasound studies in patients with polymyalgia rheumatica used case-control designs or non-representative cohorts, reducing assessment of diagnostic accuracy. This study aimed to assess the diagnostic accuracy of musculoskeletal ultrasound in two independent cohorts of patients with suspected polymyalgia rheumatica. This multicentre, diagnostic accuracy study included consecutive, glucocorticoid-naive patients with suspected polymyalgia rheumatica, referred for rheumatology evaluation at the University Medical Center Groningen, the Netherlands (retrospective cohort), between April 30, 2019, and Feb 13, 2024, and at Aarhus University Hospital, Silkeborg Regional Hospital, and Horsens Regional Hospital, Denmark (prospective cohort), between Sept 14, 2020, and June 30, 2022. The Aarhus cohort included patients older than 50 years with proximal muscle or joint pain and excluded patients with cranial symptoms suggestive of giant cell arteritis, cancer within the past 5 years, or pre-existing inflammatory rheumatic disease. No explicit referral criteria were applied in the Groningen cohort. Participants underwent protocolised clinical examination and musculoskeletal ultrasound. The reference standard was clinical diagnosis after 6 months (Groningen) or 12 months (Aarhus) of follow-up. Musculoskeletal ultrasound assessment included subacromial-subdeltoid bursitis, biceps tenosynovitis, and hip synovitis in both cohorts, plus glenohumeral synovitis and trochanteric bursitis in the Groningen cohort. A polymyalgia rheumatica ultrasound lesion count was calculated based on six (Aarhus) and ten (Groningen) sites. Diagnostic performance of individual and combined lesions was assessed using sensitivity, specificity, likelihood ratios, and receiver operating characteristic (ROC) analysis. There was no lived experience involvement in the study design or conduct. The Aarhus cohort study is registered with ClinicalTrials.gov, NCT04519580. The Groningen cohort included 92 patients patients with suspected polymyalgia rheumatica (41 [45%] male, 51 [55%] female, mean age 69 years [SD 9]), of whom 58 (63%) were diagnosed with polymyalgia rheumatica after 6-month follow-up. The Aarhus cohort included 93 patients (53 [57%] male, 40 [43%] female, mean age 71 years [SD 8]), 66 (71%) of whom had a diagnosis of polymyalgia rheumatica at 12 months. No single musculoskeletal ultrasound finding was pathognomonic for polymyalgia rheumatica. The combination of musculoskeletal ultrasound findings with the highest sensitivity was the presence of at least one inflammatory lesion (Groningen: 10-site polymyalgia rheumatica ultrasound lesion count 93% [95% CI 83-98]; Aarhus: 6-site polymyalgia rheumatica ultrasound lesion count 92% [83-98]). The combination with highest specificity was the presence of at least one inflammatory lesion in both the shoulder and hip girdles (Groningen: 85% [95% CI 69-95]; Aarhus: 93% [76-99]). ROC analysis showed an area under the curve of 0·779 (95% CI 0·675-0·883) for the 10-site count in Groningen and 0·769 (0·664-0·875) for the 6-site count in Aarhus. Musculoskeletal ultrasound performed better in distinguishing polymyalgia rheumatica from non-inflammatory conditions than from other inflammatory rheumatic diseases. Absence of shoulder and hip lesions on musculoskeletal ultrasound makes a polymyalgia rheumatica diagnosis unlikely. However, their presence requires careful clinical evaluation, as similar findings occur in other inflammatory rheumatic diseases. These findings support the use of musculoskeletal ultrasound as a potential adjunct to clinical assessment when evaluating patients with suspected polymyalgia rheumatica. FOREUM, Danish Rheumatism Association, Independent Research Fund Denmark, Ketty and Ejvind Lyngsbæks Foundation, Frimodt-Heineke's Foundation, Aase and Ejnar Danielsen's Foundation, AP Møller Foundation, Health Research Foundation of Central Denmark Region, and Regional Hospital Central Jutland Research Foundation.
-
4. Diagnosing polymyalgia rheumatica: rethinking musculoskeletal ultrasound.
PMID:日期:2026-10-01该文献暂无摘要。
-
6. Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study.
PMID:日期:2026-10-01Outcome measures for lupus arthritis that are not sensitive to change might contribute to misleading results in systemic lupus erythematosus (SLE) trials. We aimed to optimise lupus arthritis assessment by developing a novel composite disease activity measure, derived against ultrasound synovitis and incorporating participant-reported outcomes. In this cohort study we derived the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) score from baseline data in a prospective, longitudinal, multicentre study (USEFUL) of participants with SLE receiving intramuscular glucocorticoid therapy for lupus arthritis recruited from seven hospitals in England. Penalised multiple quantile (median) regression of total combined grey scale and power Doppler scores from bilateral hand and wrist joint ultrasounds on inflammatory arthritis core set variables defined by the American College of Rheumatology (tender joint count in 68 joints, swollen joint count in 66 joints, Health Assessment Questionnaire Disability Index, erythrocyte sedimentation rate [ESR], and visual analogue scales [VAS] for patient's musculoskeletal pain and disease activity and physician's musculoskeletal disease activity), and early morning stiffness severity VAS was used to derive the score. We assessed convergent construct validity, known groups validity, and responsiveness. We established thresholds of meaning for trial entry, minimal disease activity, participant acceptable symptom state, and minimal clinically important improvement using receiver operating characteristic curve analysis. A separate external validation cohort was recruited from Leeds Teaching Hospitals NHS Trust, clinical outcomes and treatment intention were collected by clinicians who were not involved in the USEFUL study. The construct validity of LAMDA within this external validation cohort was assessed, including discrimination of treatment intention and participant acceptable symptom state. People with lived experience of SLE were involved in the design and delivery of both the USEFUL study and the present study. 133 participants recruited between Oct 20, 2016, and Dec 20, 2018, were included from the USEFUL study; mean age was 47·0 years (IQR 35·0-55·0), 126 (95%) were female, seven (5%) were male, and 82 (62%) were White. The model retained four variables in the LAMDA score: swollen joint count in 66 joints, ESR, VAS for physician musculoskeletal disease activity, and participant musculoskeletal pain. High intraclass correlation (>0·99) supported directly substituting swollen joint count in 28 joints for swollen joint count in 66 joints to improve feasibility. LAMDA showed good construct validity, correlating with conventional disease activity measures, ultrasound findings, and patient-reported outcomes. LAMDA was responsive, yielding a medium-to-large early treatment effect following glucocorticoid therapy (effect size 0·40, p<0·0001). Provisional thresholds of meaning showed good logical consistency with participant characteristics and patient-reported change in musculoskeletal pain. The external validation cohort included 44 participants, recruited between Nov 15, 2017, and July 23, 2020; median age was 48·5 years (IQR 39·0-56·0), 38 (86%) were female, six (14%) were male, and 32 (73%) were White. The findings from the external validation cohort were supportive of the initial findings. LAMDA was correlated with multiple participant reported outcome measures and the proposed thresholds of meaning outperformed swollen joint counts alone in discriminating treatment intention and participant acceptable symptom state. LAMDA is a novel ultrasound-derived clinical disease activity measure that should improve the assessment of lupus arthritis in clinical trials and real-world practice. Further validation is underway in large multinational randomised controlled trials. None.
-
10. ERN ReCONNET-SLICC-SLEuro consensus on the therapeutic management of rare systemic lupus erythematosus manifestations (part 2).
PMID:日期:2026-10-01Systemic lupus erythematosus (SLE) guidelines predominantly focus on common major organ involvement. An international taskforce from three SLE expert groups (European Reference Network on Connective Tissue and Musculoskeletal Diseases, Systemic Lupus International Collaborating Clinics, and the European Lupus Society) previously developed consensus therapeutic strategies for 24 rare SLE manifestations. Here, 77 participants contributed to the development of consensus therapeutic strategies for 22 additional rare SLE manifestations, including diffuse pulmonary haemorrhage, rare cutaneous manifestations (bullous lupus, chilblain lupus, lupus tumidus, erythema multiforme, and toxic epidermal necrolysis-like lupus erythematosus), renal manifestations (interstitial nephritis and lupus podocytopathy), rare neurological manifestations (chorea, small fibre neuropathy, catatonia, and intracranial hypertension), rare gastrointestinal manifestations (protein-losing enteropathy, lupus hepatitis, intestinal pseudo-obstruction, and peritonitis), musculoskeletal manifestations (myositis and Jaccoud's arthropathy), and other rare manifestations such as uveitis, angioedema due to anti-C1 esterase inhibitor antibodies, interstitial cystitis, and lupus mastitis. These expert-based therapeutic strategies provide a framework for guiding therapeutic decisions where evidence-based recommendations might be insufficient.